Analysts’ Opinions Are Mixed on These Healthcare Stocks: Autolus Therapeutics Plc (NASDAQ: AUTL) and Cryolife (NYSE: CRY)

By Austin Angelo

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Autolus Therapeutics Plc (AUTLResearch Report) and Cryolife (CRYResearch Report).

Autolus Therapeutics Plc (AUTL)

H.C. Wainwright analyst Debjit Chattopadhyay maintained a Buy rating on Autolus Therapeutics Plc today and set a price target of $24. The company’s shares closed last Monday at $12.41, close to its 52-week low of $9.50.

Chattopadhyay said:

“Our $24 price target, is derived from a risk-adjusted, sum-of-the-parts analysis that drives our DCF model, and reflects the recent dilution from the secondary offering. Our DCF is based on: beta of 1.50, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 9.4%, and tax rate of 15% beginning in FY 2028. Our rNPV for: (1) AUTO3 is $17; (2) AUTO1 is $4; and (3) AUTO4 is $3, which are derived from probability adjusted peak sales of: (1) $432M; (2) $150M; and (3) $96M, respectively.”

According to TipRanks.com, Chattopadhyay is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -5.5% and a 39.2% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Precision BioSciences Inc, and Voyager Therapeutics Inc.

Currently, the analyst consensus on Autolus Therapeutics Plc is a Moderate Buy with an average price target of $24, representing an 80.5% upside. In a report issued on September 3, William Blair also maintained a Buy rating on the stock.

See today’s analyst top recommended stocks >>

Cryolife (CRY)

Needham analyst Michael Matson maintained a Hold rating on Cryolife today. The company’s shares closed last Monday at $27.94.

According to TipRanks.com, Matson is a 5-star analyst with an average return of 7.1% and a 62.3% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies Inc, Boston Scientific Corp, and Cardiovascular Systems.

Cryolife has an analyst consensus of Moderate Buy, with a price target consensus of $33.50.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.